Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

@article{Small1997QuetiapineIP,
  title={Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.},
  author={J. G. Chris Small and Steven Richard Hirsch and Lisa A Arvanitis and Brian Miller and C. G. G. Link},
  journal={Archives of general psychiatry},
  year={1997},
  volume={54 6},
  pages={549-57}
}
BACKGROUND Quetiapine fumarate (Seroquel [ICI 204,636]) is an atypical dibenzothiazepine antipsychotic with a greater affinity for 5-hydroxytryptamine2 (5-HT2) receptors than for D2 dopamine receptors; its efficacy in patients with schizophrenia was shown in early phase 2 trials (maximum dose, 750 mg/d). METHODS In this multicenter, double-blind, placebo-controlled trial, 286 patients hospitalized with chronic or subchronic schizophrenia (DSM-III-R) were randomized to 6 weeks of treatment… CONTINUE READING